InvestorsHub Logo
Followers 1
Posts 306
Boards Moderated 0
Alias Born 03/27/2011

Re: OTCdoc post# 1025

Thursday, 11/29/2012 8:18:02 AM

Thursday, November 29, 2012 8:18:02 AM

Post# of 3898
I think you guys have made all of the relevent points.

TEVA knew this was going to happen, and the BEST possible strategy to acquire the new shares they just announced would be right after a dilution. Bingo! Cheaper shares.

I had the initial reaction about a dilution, but this is positive. TEVA may also buy some of this offering, and I hope we find out soon. I think Rexahn has gotten a lot smarter about how they are spending their money, focusing on higher percentage chance of being successful: drugs on their oncology side.

Teva buying shares I believe is a setup for them to purchase Rexahn. They didn't have to do that, as they could have just contributed to RX-3117. The stock was optional. The only thing I am surprised about is Rexahn attempting this at this low a price. I didn't think they would be able to do it (wait and see on that one) but we don't know if they already had interested parties that want in cheap. This is better than buying on the open market.

So if Rexahn pulls this off, I wonder where they will spend their money first. They have a few options besides 3117.